The changing face of antibiotic therapy.
Antimicrobial resistance is one of the biggest challenges facing the NHS. Part of the solution is education and improved prescribing by doctors. Janssen-Cilag sponsored a meeting in May 2009 in Glasgow focussing on doripenem, a new carbapenem. This report highlights the role of doripenem in health-care-associated infection control.
D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D015780:Carbapenems / Q000191:economics / Q000627:therapeutic use*; D003428:Cross Infection / Q000188:drug therapy* / Q000191:economics; D003692:Delayed-Action Preparations; D000077726:Doripenem; D024881:Drug Resistance, Bacterial; D006801:Humans; D017053:Infection Control / Q000191:economics / Q000379:methods*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D015780:Carbapenems; D003692:Delayed-Action Preparations; D000077726:Doripenem